Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly(<scp>ADP</scp>‐ribose) polymerase proteins inhibitors for solid tumours-Reference-Cited by-同舟云学术

Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly(ADP‐ribose) polymerase proteins inhibitors for solid tumours

Published:2023-03-23 Issue:3 Volume:201 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Almanza‐Huante Emmanuel¹^ORCID,Bataller Alex¹^ORCID,Urrutia Samuel²,Gener‐Ricos Georgina¹,Briski Robert Edward¹,Kanagal‐Shamanna Rashmi³^ORCID,Lu Karen H.⁴,Westin Shannon N.⁴,Yap Timothy A.⁵,Takahashi Koichi¹,Ravandi Farhad¹,Alvarado Yesid¹,Kadia Tapan¹,Sasaki Koiji¹^ORCID,Kantarjian Hagop M.¹,Garcia‐Manero Guillermo¹^ORCID

Affiliation:

1. Department of Leukemia, MD Anderson Cancer Center The University of Texas Houston Texas USA

2. Cancer Medicine, MD Anderson Cancer Center The University of Texas Houston Texas USA

3. Department of Hematopathology, MD Anderson Cancer Center The University of Texas Houston Texas USA

4. Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center The University of Texas Houston Texas USA

5. Department of Investigational Cancer Therapeutics (Phase I Program), MD Anderson Cancer Center The University of Texas Houston Texas USA

Funder

University of Texas MD Anderson Cancer Center

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18766

Reference13 articles.

1. Therapy-Related Myeloid Neoplasms

2. Therapy-related myeloid neoplasms

3. PARP inhibitors: Synthetic lethality in the clinic

4. PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword

5. PARP and PARG inhibitors in cancer treatment

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms;Cancer Medicine;2024-03

3. The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia;Therapeutic Advances in Hematology;2023-01